A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.

ClinicalTrials.gov ID: NCT02960854

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02960854. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936558 (Nivolumab) in Participants With Severe Sepsis or Septic Shock.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.

Study identification

NCT ID: NCT02960854
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 38 participants

Conditions and interventions

Conditions

Severe Sepsis

Interventions

Nivolumab Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 7, 2016 (Actual)
Primary completion: Jan 5, 2018 (Actual)
Completion: Jan 5, 2018 (Actual)
Last update posted: Apr 23, 2019

2016 – 2018

United States locations

U.S. sites: 16
U.S. states: 13
U.S. cities: 15

Facility	City	State	ZIP	Site status
Uc Davis Medical Center	Sacramento	California	95817	—
Univ. Of Colorado Health	Colorado Springs	Colorado	80909	—
Denver Health Medical Center	Denver	Colorado	80204	—
University Of Florida	Gainesville	Florida	32610	—
Pulmonary And Critical Care Of Atlanta	Atlanta	Georgia	30303	—
Osf Saint Francis Medical Center	Peoria	Illinois	61637	—
University Of Kentucky	Lexington	Kentucky	40536	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Beth Israel Deaconess Medical Center (BIDMC)	Boston	Massachusetts	02215	—
Baystate Medical Center	Springfield	Massachusetts	01199	—
University of Michigan, Division of Acute Care Surgery	Ann Arbor	Michigan	48109-5008	—
Washington University School Of Medicine	St Louis	Missouri	63110	—
Duke University Medical Center	Durham	North Carolina	27710	—
The Ohio State University	Columbus	Ohio	43210	—
UPMC	Pittsburgh	Pennsylvania	15261-2500	—
Harborview Medical Center	Seattle	Washington	98104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02960854, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 23, 2019 · Synced Nov 13, 2026